lapatinib-gsk filmtabletten
glaxosmithkline ag - lapatinibum - filmtabletten - lapatinibum 250 mg ut lapatinibi ditosilas monohydricus 405 mg, cellulosum microcristallinum, povidonum k 30, carboxymethylamylum natricum a, magnesii stearas, Überzug: hypromellosum, macrogolum 400, polysorbatum 80, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto, natrium 2.82 mg. - zytostatikum - synthetika
lapatinib ratiopharm 250 mg filmtabletten
ratiopharm arzneimittel vertriebs-gmbh - lapatinibditosilat monohydrat -
lapatinib teva 250 mg filmtabletten
ratiopharm arzneimittel vertriebs-gmbh - lapatinibditosilat monohydrat -
mekinist
novartis europharm limited - trametinib - melanom - antineoplastische mittel - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 und 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-small cell lung cancer (nsclc)in kombination mit trametinib dabrafenib ist angezeigt zur behandlung von erwachsenen patienten mit fortgeschrittenem nicht-kleinzelligem lungenkrebs mit einer braf-v600-mutation.
gavreto 100 mg hartkapseln
roche pharma (schweiz) ag - pralsetinibum - hartkapseln - pralsetinibum 100 mg, hypromellosum, cellulosum microcristallinum, natrii hydrogenocarbonas corresp. natrium 22.3 mg, acidum citricum, magnesii stearas, amylum pregelificatum, kapselhülle: hypromellosum, e 171, e 133, drucktinte: lacca, propylenglycolum, ammonii hydroxidum, kalii hydroxidum, e 171, pro capsula. - nichtkleinzelliges lungenkarzinom mit rearrangement des ret (rearranged during transfection)-gens; ret-fusion-positives schilddrüsenkarzinom - synthetika
alecensa 150 mg hartkapseln
roche pharma (schweiz) ag - alectinibum - hartkapseln - alectinibum 150 mg ut alectinibi hydrochloridum, lactosum monohydricum 33.67 mg, hydroxypropylcellulosum, natrii laurilsulfas corresp. natrium 6 mg, carmellosum calcicum, magnesii stearas, kapselhülle: carrageenanum, kalii chloridum, e 171, cera carnauba, maydis amylum, hypromellosum, drucktinte: e 172 (rubrum), e 172 (flavum), e 132, cera carnauba, lacca, polyglyceroli-3 mono-oleas, pro capsula. - nicht-kleinzelliges lungenkarzinom (nsclc) - synthetika
mekinist 0.5mg filmtabletten
novartis pharma schweiz ag - trametinibum - filmtabletten - trametinibum 0.5 mg ut trametinibi dimethylis sulfoxidi solvatum, mannitolum, cellulosum microcristallinum, hypromellosum, carmellosum natricum conexum, natrii laurilsulfas, silica colloidalis hydrica, magnesii stearas, Überzug: hypromellosum, macrogolum, e 171, e 172 (flavum), pro compresso obducto corresp. natrium 0.199 mg. - melanom, nicht-kleinzelliges lungenkarzinom - synthetika
mekinist 2mg filmtabletten
novartis pharma schweiz ag - trametinibum - filmtabletten - trametinibum 2 mg ut trametinibi dimethylis sulfoxidi solvatum, mannitolum, cellulosum microcristallinum, hypromellosum, carmellosum natricum conexum, natrii laurilsulfas, silica colloidalis hydrica, magnesii stearas, Überzug: hypromellosum, macrogolum, polysorbatum 80, e 171, e 172 (rubrum), pro compresso obducto corresp. natrium 0.232 mg. - melanom, nicht-kleinzelliges lungenkarzinom - synthetika
tyverb filmtabletten
novartis pharma schweiz ag - lapatinibum - filmtabletten - lapatinibum 250 mg ut lapatinibi ditosilas monohydricus 405 mg, cellulosum microcristallinum, povidonum k 30, carboxymethylamylum natricum a, magnesii stearas, Überzug: hypromellosum, macrogolum 400, polysorbatum 80, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto, natrium 2.82 mg. - zytostatikum - synthetika
gavreto
roche registration gmbh - pralsetinib - karzinom, nicht kleinzellige lunge - antineoplastische mittel - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.